scholarly journals A meta‐analysis of microRNA networks regulated by melatonin in cancer: Portrait of potential candidates for breast cancer treatment

2020 ◽  
Vol 69 (4) ◽  
Author(s):  
Luiz Gustavo de Almeida Chuffa ◽  
Robson Francisco Carvalho ◽  
Luis Antônio Justulin ◽  
Sarah Santiloni Cury ◽  
Fábio Rodrigues Ferreira Seiva ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Meta Analysis ◽  
Breast Cancer Treatment ◽  
Microrna Networks

scholarly journals Platinum-based therapy for triple-negative breast cancer treatment: A meta-analysis

2015 ◽  
Vol 3 (3) ◽  
pp. 720-724 ◽  
Author(s):  
MUYOU TIAN ◽  
YAHUA ZHONG ◽  
FUXIANG ZHOU ◽  
CONGHUA XIE ◽  
YUNFENG ZHOU ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Meta Analysis ◽  
Breast Cancer Treatment

scholarly journals Risk factors, prevalence, and course of severe fatigue after breast cancer treatment: a meta-analysis involving 12 327 breast cancer survivors

2016 ◽  
Vol 27 (6) ◽  
pp. 965-974 ◽  
Author(s):  
H.J.G. Abrahams ◽  
M.F.M. Gielissen ◽  
I.C. Schmits ◽  
C.A.H.H.V.M. Verhagen ◽  
M.M. Rovers ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Cancer Survivors ◽  
Cancer Treatment ◽  
Breast Cancer Survivors ◽  
Meta Analysis ◽  
Breast Cancer Treatment ◽  
Severe Fatigue

scholarly journals Efficacy and safety of Nab-paclitaxel in breast cancer: a meta-analysis

2019 ◽  
Author(s):  
Upendra Yadav ◽  
Pradeep Kumar ◽  
Vandana Rai
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Side Effects ◽  
Cancer Treatment ◽  
Meta Analysis ◽  
Progression Free Survival ◽  
Breast Cancer Treatment ◽  
Efficacy And Safety ◽  
Free Survival ◽  
Key Terms

AbstractWorldwide breast cancer is the leading cause of cancer related death in women. Paclitaxel is an effective drug used for the treatment of breast cancer but it has many side effects. Nab-paclitaxel (nanoparticle albumin-bound paclitaxel) is an FDA approved drug for the treatment of breast cancer. Currently many clinical trials are conducted to deliver nab-paclitaxel into the tumor cells. But the efficacy and safety of this nab-paclitaxel over conventional paclitaxel still remains questionable. So, we performed a meta-analysis to evaluate the efficacy and safety of nab-paclitaxel in breast cancer treatment.Electronic databases were searched for the suitable studies using key terms “nab-paclitaxel”, “paclitaxel”, and “clinical trial” with the combination of “breast cancer” up to August 11, 2019. Risk ratio (RR) and odds ratio (OR) with corresponding 95% confidence intervals (CIs) were calculated. All statistical analyses were performed by the Open Meta-Analyst program. A total of eight studies which fulfilled our criteria were included in this study. For efficacy we retrieved data of 12 months progression free survival, 24 months progression free survival, and overall survival (up to 3 years) and for the safety we took data of nausea, anemia, leukopenia, neutropenia, fatigue, diarrhea and pain.We did not found any difference in efficacy of nab-paclitaxel over paclitaxel (12 months progression free survival-RRFE= 0.86, 95%CI= 0.77-0.97, p= 0.02, I2= 25.07%; 24 months progression free survival-RRFE= 0.86, 95% CI= 0.64-1.16, p= 0.34, I2= 0%; and 3 years survival-RRFE= 1.20, 95%CI= 0.92-1.56, p= 0.16, I2= 37.55%). The meta-analysis of studies used nab-paclitaxel showed reduced adverse effect of anemia (ORFE= 1.66, 95% CI= 1.26-2.19; p= <0.001; I2= 0%) and leukopenia (ORFE= 1.37; 95%CI= 1.06-1.75; p= 0.01; I2= 48.63%). However, in case of other adverse effects no significant association was found with nab-paclitaxel (nausea-ORFE=1.15, 95%CI= 0.94-1.41, p= 0.15, I2= 50.12%; neutropenia-ORRE= 0.75, 95%CI= 0.30-1.87, p= 0.54, I2= 94.45%; fatigue-ORRE= 1.11, 95%CI= 0.77-1.62, p= 0.55, I2= 56.02; diarrhea-ORFE= 1.11, 95%CI= 0.77-1.62, p= 0.55; I2= 34.26; pain-ORRE= 1.15, 95%CI= 0.78-1.69, p= 0.45, I2= 52.96%).In conclusion the use of nab-paclitaxel has reduces the side effects of anemia and leukopenia in breast cancer treatment in comparison to paclitaxel but nab-paclitaxel has no effect on the overall survival of the patients.

scholarly journals Lymphoedema After Breast Cancer Treatment is Associated With Higher Body Mass Index: A Systematic Review and Meta-Analysis

2019 ◽  
Vol Vol 3 (No 2) ◽  
pp. 178-192
Author(s):  
Astère Manirakiza ◽  
Laurent Irakoze ◽  
Lin Shui ◽  
Sébastien Manirakiza ◽  
Louis Ngendahayo
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Body Mass Index ◽  
Cancer Treatment ◽  
Body Mass ◽  
Meta Analysis ◽  
Breast Cancer Treatment
Sign in / Sign up

Export Citation Format

Share Document